Anticholinesterase abuse in myasthenia gravis.
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008564:Membrane Potentials; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000628:therapy; D009388:Neostigmine / Q000008:administration & dosage / Q000633:toxicity; D009469:Neuromuscular Junction / Q000502:physiology / Q000648:ultrastructure; D010956:Plasmapheresis; D011729:Pyridostigmine Bromide / Q000008:administration & dosage; D051381:Rats; D011950:Receptors, Cholinergic / Q000032:analysis; D013256:Steroids / Q000008:administration & dosage; D013570:Synaptic Membranes / Q000648:ultrastructure; D013934:Thymectomy
D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D013256:Steroids; D009388:Neostigmine; D011729:Pyridostigmine Bromide; D000109:Acetylcholine